Aptar Pharma and Dianosic Team Up on Chronic Rhinosinusitis Solution

Aptar Pharma has negotiated an exclusive partnership agreement with Dianosic, a French biotech company pioneering intranasal therapeutic solutions, to develop an Active Resorbable Intranasal Scaffold (ARIS) technology platform.

Dianosic’s intranasal insert is bioresorbable and aims to address the unmet needs of delivering drugs locally over extended periods for treating chronic allergic rhinitis (CAR) and chronic rhinosinusitis (CRS). This collaboration would additionally explore Nose-to-Brain (N2B) opportunities, especially in neuropsychiatric and neurodegenerative diseases.

“We are thrilled to join forces with Aptar Pharma as it marks a major step towards making our drug-eluting resorbable Intranasal Scaffold platform accessible worldwide,” Dianosic Co-Founder/CEO Philippe Bastide said. “This alliance supports our commitment to improving intranasal therapeutic options for patients with chronic nasal conditions.”

An “insert and forget” intranasal drug delivery solution aims to address patient adherence to treatment challenges, thus maximizing patient quality-of-life. Moreover, it also aims to respond to physician needs in terms of efficacy, safety and ease-of-use.

Under the agreement, Aptar Pharma will invest in Dianosic and be part of its strategic committee, while promoting the technology to its customers and exploring opportunities to complement the platform with Aptar’s suite of comprehensive services.

“This partnership with Dianosic expands our commitment to deliver patient-centric solutions by leveraging the potential of intranasal drug-delivery,” Aptar Pharma Prescription President Alex Theodorakis stated. “This transformative innovation represents a promising advancement in the management of chronic rhinitis and sinusitis, and we are proud to support the ARIS journey to market.”

The partnership combines Dianosic’s clinical innovation and proprietary design with Aptar Pharma’s expertise and support in nasal drug delivery. This partnership will also provide the opportunity to explore the potential of this technology in Nose-To-Brain (N2B) drug delivery.

“This collaboration further reinforces Aptar Pharma’s leadership in nasal drug delivery by expanding our portfolio and proposing disruptive solutions to our customers,” Theodorakis added. “By leveraging Aptar Pharma’s expertise—alongside Noble’s capabilities in human factor studies and patient onboarding, and Aptar CSP active material sciences offering—this partnership with Dianosic aims to bring to market a major value-added solution that enhances patient outcomes and delivers value to pharmaceutical partners.”

As a global developer of drug and consumer product dosing, dispensing and protection technologies, Aptar Pharma uses insights, design, engineering, and science to create dosing, dispensing and protective packaging technologies for leading brands.

Dianosic designs intranasal solutions resolving patients adherence to medication challenges. The company collaborates with healthcare professionals to provide solutions that change patients’ lives in chronic rhinitis, chronic rhinosinusitis, and intranasal bleeding (epistaxis).